NCT06616636View on ClinicalTrials.gov

A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

PHASE1RecruitingINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

January 30, 2025

Primary Completion Date

August 27, 2027

Study Completion Date

August 27, 2029

Conditions

Myelodysplastic SyndromeAcute Myeloid Leukemia

Interventions

DRUG

Azacitidine

Given by IV

DRUG

Rezatapopt

Given orally with food

Trial Locations (1)

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

PMV Pharmaceuticals, Inc

All Listed Sponsors

collaborator

Memorial Sloan Kettering Cancer Center (MSK)

UNKNOWN

collaborator

PMV Pharmaceuticals, Inc

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER